Phase 2 Solid Cancers Clinical Trials
7 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor
Ovarian CancerEndometrial CancerBreast Cancer (Locally Advanced or Metastatic)+2 more
Shenzhen Ionova Life Sciences Co., Ltd.201 enrolled1 locationNCT07612891
Recruiting
Phase 1Phase 2
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Advanced Solid Cancers
BioNTech SE245 enrolled10 locationsNCT07186842
Recruiting
Phase 2
Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
Lung CancerRadiotherapyImmune Checkpoint Inhibitor+1 more
Tianjin Medical University Cancer Institute and Hospital30 enrolled3 locationsNCT07058948
Recruiting
Phase 2Phase 3
Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients
Advanced Solid Cancers
Intra-IMMUSG Pte Ltd52 enrolled4 locationsNCT07290088
Recruiting
Phase 1Phase 2
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Endometrial CancerGastric (Stomach) CancerNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Beijing Tide Pharmaceutical Co., Ltd266 enrolled3 locationsNCT07371663
Recruiting
Phase 2
Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
Drug ResistanceMetastatic Solid CancersRadiotherapy+3 more
Chuangzhen Chen48 enrolled1 locationNCT07071103
Recruiting
Phase 2
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors
Solid Cancers
Tianjin Medical University Second Hospital15 enrolled1 locationNCT07170293